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extracorporeal membrane oxygenator
thrombosis without heparin resistance and
with thrombocytopenia
Huai-Wu He, Xiang Zhou, Yun Long, Xiao-ting Wang, Qing Zhang, Hua Zhao, Hong-min Zhang,
Wen-zhao Chai and Da-Wei Liu*Anticoagulation is widely used for preventing membrane
oxygenator thrombosis during extracorporeal membrane
oxygenation (ECMO) therapy while anti-platelets are
rarely used, especially in patients with thrombocytopenia
[1]. Here we report a case of successfully using anti-platelet
treatment to prevent recurrent extracorporeal membrane
oxygenator thrombosis in a fulminant myocarditis (FM)
patient.
A 32-year-old man was admitted to our hospital with
FM, with 10% left ventricular ejection fraction. After his
arrival, he had a sudden onset of ventricular fibrillation and
developed cardiac arrest, so cardiopulmonary resuscitation
was performed. With high doses of vasoactive medications,
he was transferred to the ICU, where venoarterial ECMO
was initiated. Continuous infusion of heparin was used for
anticoagulation, and activated partial thromboplastin time
(aPTT) was titrated up to about 70 seconds. The rotational
speed of the pump was about 4,500 rpm, and the blood
flow of the pump was 3.9 L/minute. On the second day of
ECMO therapy, the membrane oxygenator developed
thrombosis, so we replaced it with a new one. Furthermore,
we intensified the systemic anticoagulation with a higher
aPTT target, about 70 to 90 seconds. However, the
membrane oxygenator still developed thrombosis on
the fourth day of ECMO initiation, and the oxygenator
was replaced again. In addition, there was no clinical
evidence of hemolysis or thrombosis at other body sites,
and the platelet count decreased to 31,000/mm3. Thus, we
inferred that the membrane oxygenator may have
abnormally activated the platelets, resulting in thrombotic
clot formation. As a result we combined the anti-platelet* Correspondence: tjmuhhw@163.com
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unless otherwise stated.treatment (aspirin administered with a first dose of
300 mg and then 100 mg per day) with heparin therapy.
After that, oxygenator thrombosis did not occur
again, and the platelet count gradually increased to
123,000/mm3 without bleeding complications. The patient
was weaned from ECMO 15 days after his admission. The
related data for coagulation and anti-platelet treatment
are summarized in Table 1.
Ranucci and colleagues [2] reported that inadequate
thrombin suppression by heparin may induce intravascular
and extravascular thrombosis, which would result in
coagulation factors and platelet consumption, and cause
more bleeding and require larger transfusions. However,
there was no evidence of insufficient anticoagulation and
heparin resistance in our case presented here. Moreover, a
higher target of anticoagulation was not effective for
preventing oxygenator thrombosis, and the recurrent
thrombosis happened only in the oxygenator but not
at other sites of the body. Therefore, it seemed that
the combination of anti-platelet treatment would be
appropriate. However, thrombopenia is another dilemma.
In our opinion, the primary cause of oxygenator thrombosis
and thrombopenia was abnormal activation of the platelets
in the membrane oxygenator, which deserved medical
intervention. Lehot and colleagues [3] recently showed that
oxygenator thrombosis occurred without heparin resistance
in coronary artery bypass graft surgery with normothermic
extracorporeal circulation in polycytemia vera. To the best
of our knowledge, this is the first case report of the use of
anti-platelet therapy to prevent oxygenator thrombosis
without heparin resistance and with thrombopenia in FM.This is an Open Access article distributed under the terms of the Creative
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Table 1 Related data for anticoagulation and anti-platelet therapy during extracorporeal membrane oxygenation
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13
Plt 202 113 63 36 31 37 39 40 54 66 73 92 123
aPTT 77 68 91 97 65 58 56 61 60 79 77 74 64
Aspirin - - - 300 100 100 100 100 100 100 100 100 100
Event Ex-* Ex-*
D1 is the first day of extracorporeal membrane oxygenation initiation. Plt, platelet count (×103/ml3); Aspirin, aspirin dose (mg); aPTT, activated partial
thromboplastin time (seconds); Ex-*, oxygenator exchanged.
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aPTT: activated partial thromboplastin time; ECMO: extracorporeal membrane
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